00:00 , Jan 18, 2018 |  BioCentury  |  Emerging Company Profile

Computing brain entry

1st Biotherapeutics Inc. aims to develop a pipeline of first- or best-in-class molecules for CNS diseases by using computational tools to achieve better blood-brain barrier penetration and PK properties than marketed drugs against the same...
22:04 , Dec 1, 2017 |  BC Week In Review  |  Company News

1ST Bio partners with Neuraly for PD

1ST Bio Therapeutics Inc. (Seongnam, South Korea) partnered with Neuraly Inc. to co-develop brain penetrant inhibitors of ABL proto-oncogene 1 non-receptor tyrosine kinase (ABL; ABL1) to treat Parkinson's disease. Neuraly spun out of Johns Hopkins...
00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
19:38 , May 26, 2017 |  BC Extra  |  Clinical News

Team identifies potential target pathway for ALS

In a paper published in Science Translational Medicine , researchers at Kyoto University (Kyoto, Japan) identified the Src/ ABL proto-oncogene 1 non-receptor tyrosine kinase (ABL; ABL1) pathway as a potential target to treat amyotrophic lateral...
20:36 , Apr 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Allosteric en-ABL-ement

Novartis AG has developed a new strategy to prevent leukemias from becoming resistant to its CML drugs against BCR-ABL . Rather than combining the inhibitors with other classes of cancer therapies, the company is doubling...
19:59 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest inhibiting ABL1 or its downstream effector MLL4 could help treat hepatic steatosis. In a mouse model of diet-induced hepatic steatosis, liver levels of ABL1 were higher than in normal...